Sepsis and cell stress: a study of HO-1/CREB3
Part of Infections clinical trials.
This trial is studying how a specific protein (HO-1/CREB3) affects stress inside cells (called Golgi stress) in patients with sepsis. It may help doctors understand sepsis better and find new ways to treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with sepsis within the last 48 hours.
- You can understand the risks of the study and give permission to participate (or a family member or guardian can do so for you).
- You are not pregnant, breastfeeding, or in the period right after giving birth.
- You do not have breast cancer, HIV, or syphilis.
- You are not currently in any other experimental treatment study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the immune system works in people who are critically ill with sepsis. By understanding these changes, doctors hope to find better ways to treat this serious condition.
This trial studies treatments for sepsis, a serious infection complication, in ICU patients. It aims to find better ways to care for critically ill patients with sepsis.
This study looks at different types (“endotypes”) of sepsis in adults to better understand what’s happening in the body and how patients may respond. You might be asked to provide information and samples as the study tries to sort sepsis into meaningful subgroups.
This trial tests a treatment made from human umbilical cord cells to help the body fight severe infections (sepsis). It might reduce inflammation and improve recovery.
This trial studies people with and without sepsis in the ICU to understand why some get very sick from infections. It aims to find better ways to predict who will have complications and guide treatment.
This study looks at a type of immune cell called 'memory CD8+ T cells' in patients with sepsis, a life-threatening response to infection. The goal is to see if these cells are linked to how severe the sepsis is and the risk of dying. This may help doctors better predict outcomes for people with sepsis.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.